Researchers from Astrazeneca plc and Karolinska Institutet have described the positron emission tomography (PET) evaluation of [11C]AZD-2423, a chemokine receptor type 2 (CCR2) radioligand in non-human primate (NHP) brain imaging. CCR2 is essential in immune cell migration control. It is mainly expressed in microglia and monocytes and closely linked to the brain’s immune defense.